Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00732251 · ClinicalTrials.gov registry record · Phase 4
Allopurinol Maintenance Study for Bipolar Disorder
A Phase 4 study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT00732251 is a Phase 4 study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 15 participants.
The verdict
NCT00732251, a Phase 4 study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy of allopurinol as an augmentation agent for the prevention of mania in bipolar disorder patients with currently stable mood.
Interventions
- DRUG Allopurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00732251
The ClinicalTrials.gov registry entry for NCT00732251 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allopurinol is the first listed.
NCT00732251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00732251 about?
NCT00732251 is a clinical study titled "Allopurinol Maintenance Study for Bipolar Disorder". The purpose of this study is to investigate the efficacy of allopurinol as an augmentation agent for the prevention of mania in bipolar disorder patients with currently stable mood.
What is the current status of trial NCT00732251?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2008-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00732251?
The interventions under investigation include: Allopurinol (DRUG).
Who is sponsoring clinical trial NCT00732251?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.